Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor

Timmy Mani, Degang Liu, Donghui Zhou, Liwei Li, William Eric Knabe, Fang Wang, Kyungsoo Oh, Samy O. Meroueh

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The urokinase receptor (uPAR) is a cell-surface protein that is part of an intricate web of transient and tight protein interactions that promote cancer cell invasion and metastasis. Here, we evaluate the binding and biological activity of a new class of pyrrolidinone and piperidinone compounds, along with derivatives of previously-identified pyrazole and propylamine compounds. Competition assays revealed that the compounds displace a fluorescently labeled peptide (AE147-FAM) with inhibition constant (Ki) values ranging from 6 to 63 μM. Structure-based computational pharmacophore analysis followed by extensive explicit-solvent molecular dynamics (MD) simulations and free energy calculations suggested the pyrazole-based and piperidinone-based compounds adopt different binding modes, despite their similar two-dimensional structures. In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM. One pyrazole-based compound impaired MDA-MB-231 invasion, adhesion, and migration in a concentration-dependent manner, while the piperidinone inhibited only invasion. The pyrazole derivative inhibited matrix metalloprotease-9 (gelatinase) activity in a concentration-dependent manner, while the piperidinone showed no effect suggesting different mechanisms for inhibition of cell invasion. Signaling studies further highlighted these differences, showing that pyrazole compounds completely inhibited ERK phosphorylation and impaired HIF1α and NF-κB signaling, while pyrrolidinones and piperidinones had no effect. Annexin V staining suggested that the effect of the pyrazole-based compound on proliferation was due to cell killing through an apoptotic mechanism. The compounds identified represent valuable leads in the design of further derivatives with higher affinities and potential probes to unravel the protein-protein interactions of uPAR. Optimization through computation: Pyrazole-, propylamine-, pyrrolidinone- and piperidinone-containing compounds were designed, synthesized and evaluated as inhibitors of urokinase receptor (uPAR), a cell-surface protein known to be involved in cancer cell invasion and metastasis.

Original languageEnglish (US)
Pages (from-to)1963-1977
Number of pages15
JournalChemMedChem
Volume8
Issue number12
DOIs
StatePublished - Dec 1 2013

Fingerprint

Pyrrolidinones
Urokinase-Type Plasminogen Activator
Molecules
Propylamines
Cells
Derivatives
Membrane Proteins
Adenocarcinoma
Neoplasm Metastasis
Gelatinases
Phosphorylation
Proteins
pyrazole
Annexin A5
Cell proliferation
Metalloproteases
Molecular Dynamics Simulation
Cytotoxicity
Bioactivity
Free energy

Keywords

  • cancer
  • inhibitors
  • invasion
  • metastasis
  • protein-protein interaction
  • small molecules
  • uPAR
  • urokinase
  • urokinase receptors

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry
  • Molecular Medicine

Cite this

Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor. / Mani, Timmy; Liu, Degang; Zhou, Donghui; Li, Liwei; Knabe, William Eric; Wang, Fang; Oh, Kyungsoo; Meroueh, Samy O.

In: ChemMedChem, Vol. 8, No. 12, 01.12.2013, p. 1963-1977.

Research output: Contribution to journalArticle

Mani, Timmy ; Liu, Degang ; Zhou, Donghui ; Li, Liwei ; Knabe, William Eric ; Wang, Fang ; Oh, Kyungsoo ; Meroueh, Samy O. / Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor. In: ChemMedChem. 2013 ; Vol. 8, No. 12. pp. 1963-1977.
@article{49c5159382ef499aaf54abe712714c35,
title = "Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor",
abstract = "The urokinase receptor (uPAR) is a cell-surface protein that is part of an intricate web of transient and tight protein interactions that promote cancer cell invasion and metastasis. Here, we evaluate the binding and biological activity of a new class of pyrrolidinone and piperidinone compounds, along with derivatives of previously-identified pyrazole and propylamine compounds. Competition assays revealed that the compounds displace a fluorescently labeled peptide (AE147-FAM) with inhibition constant (Ki) values ranging from 6 to 63 μM. Structure-based computational pharmacophore analysis followed by extensive explicit-solvent molecular dynamics (MD) simulations and free energy calculations suggested the pyrazole-based and piperidinone-based compounds adopt different binding modes, despite their similar two-dimensional structures. In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM. One pyrazole-based compound impaired MDA-MB-231 invasion, adhesion, and migration in a concentration-dependent manner, while the piperidinone inhibited only invasion. The pyrazole derivative inhibited matrix metalloprotease-9 (gelatinase) activity in a concentration-dependent manner, while the piperidinone showed no effect suggesting different mechanisms for inhibition of cell invasion. Signaling studies further highlighted these differences, showing that pyrazole compounds completely inhibited ERK phosphorylation and impaired HIF1α and NF-κB signaling, while pyrrolidinones and piperidinones had no effect. Annexin V staining suggested that the effect of the pyrazole-based compound on proliferation was due to cell killing through an apoptotic mechanism. The compounds identified represent valuable leads in the design of further derivatives with higher affinities and potential probes to unravel the protein-protein interactions of uPAR. Optimization through computation: Pyrazole-, propylamine-, pyrrolidinone- and piperidinone-containing compounds were designed, synthesized and evaluated as inhibitors of urokinase receptor (uPAR), a cell-surface protein known to be involved in cancer cell invasion and metastasis.",
keywords = "cancer, inhibitors, invasion, metastasis, protein-protein interaction, small molecules, uPAR, urokinase, urokinase receptors",
author = "Timmy Mani and Degang Liu and Donghui Zhou and Liwei Li and Knabe, {William Eric} and Fang Wang and Kyungsoo Oh and Meroueh, {Samy O.}",
year = "2013",
month = "12",
day = "1",
doi = "10.1002/cmdc.201300340",
language = "English (US)",
volume = "8",
pages = "1963--1977",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "12",

}

TY - JOUR

T1 - Probing binding and cellular activity of pyrrolidinone and piperidinone small molecules targeting the urokinase receptor

AU - Mani, Timmy

AU - Liu, Degang

AU - Zhou, Donghui

AU - Li, Liwei

AU - Knabe, William Eric

AU - Wang, Fang

AU - Oh, Kyungsoo

AU - Meroueh, Samy O.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - The urokinase receptor (uPAR) is a cell-surface protein that is part of an intricate web of transient and tight protein interactions that promote cancer cell invasion and metastasis. Here, we evaluate the binding and biological activity of a new class of pyrrolidinone and piperidinone compounds, along with derivatives of previously-identified pyrazole and propylamine compounds. Competition assays revealed that the compounds displace a fluorescently labeled peptide (AE147-FAM) with inhibition constant (Ki) values ranging from 6 to 63 μM. Structure-based computational pharmacophore analysis followed by extensive explicit-solvent molecular dynamics (MD) simulations and free energy calculations suggested the pyrazole-based and piperidinone-based compounds adopt different binding modes, despite their similar two-dimensional structures. In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM. One pyrazole-based compound impaired MDA-MB-231 invasion, adhesion, and migration in a concentration-dependent manner, while the piperidinone inhibited only invasion. The pyrazole derivative inhibited matrix metalloprotease-9 (gelatinase) activity in a concentration-dependent manner, while the piperidinone showed no effect suggesting different mechanisms for inhibition of cell invasion. Signaling studies further highlighted these differences, showing that pyrazole compounds completely inhibited ERK phosphorylation and impaired HIF1α and NF-κB signaling, while pyrrolidinones and piperidinones had no effect. Annexin V staining suggested that the effect of the pyrazole-based compound on proliferation was due to cell killing through an apoptotic mechanism. The compounds identified represent valuable leads in the design of further derivatives with higher affinities and potential probes to unravel the protein-protein interactions of uPAR. Optimization through computation: Pyrazole-, propylamine-, pyrrolidinone- and piperidinone-containing compounds were designed, synthesized and evaluated as inhibitors of urokinase receptor (uPAR), a cell-surface protein known to be involved in cancer cell invasion and metastasis.

AB - The urokinase receptor (uPAR) is a cell-surface protein that is part of an intricate web of transient and tight protein interactions that promote cancer cell invasion and metastasis. Here, we evaluate the binding and biological activity of a new class of pyrrolidinone and piperidinone compounds, along with derivatives of previously-identified pyrazole and propylamine compounds. Competition assays revealed that the compounds displace a fluorescently labeled peptide (AE147-FAM) with inhibition constant (Ki) values ranging from 6 to 63 μM. Structure-based computational pharmacophore analysis followed by extensive explicit-solvent molecular dynamics (MD) simulations and free energy calculations suggested the pyrazole-based and piperidinone-based compounds adopt different binding modes, despite their similar two-dimensional structures. In cells, pyrazole-based compounds showed significant inhibition of breast adenocarcinoma (MDA-MB-231) and pancreatic ductal adenocarcinoma (PDAC) cell proliferation, but piperidinone-containing compounds exhibited no cytotoxicity even at concentrations of 100 μM. One pyrazole-based compound impaired MDA-MB-231 invasion, adhesion, and migration in a concentration-dependent manner, while the piperidinone inhibited only invasion. The pyrazole derivative inhibited matrix metalloprotease-9 (gelatinase) activity in a concentration-dependent manner, while the piperidinone showed no effect suggesting different mechanisms for inhibition of cell invasion. Signaling studies further highlighted these differences, showing that pyrazole compounds completely inhibited ERK phosphorylation and impaired HIF1α and NF-κB signaling, while pyrrolidinones and piperidinones had no effect. Annexin V staining suggested that the effect of the pyrazole-based compound on proliferation was due to cell killing through an apoptotic mechanism. The compounds identified represent valuable leads in the design of further derivatives with higher affinities and potential probes to unravel the protein-protein interactions of uPAR. Optimization through computation: Pyrazole-, propylamine-, pyrrolidinone- and piperidinone-containing compounds were designed, synthesized and evaluated as inhibitors of urokinase receptor (uPAR), a cell-surface protein known to be involved in cancer cell invasion and metastasis.

KW - cancer

KW - inhibitors

KW - invasion

KW - metastasis

KW - protein-protein interaction

KW - small molecules

KW - uPAR

KW - urokinase

KW - urokinase receptors

UR - http://www.scopus.com/inward/record.url?scp=84889886981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889886981&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201300340

DO - 10.1002/cmdc.201300340

M3 - Article

C2 - 24115356

AN - SCOPUS:84889886981

VL - 8

SP - 1963

EP - 1977

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 12

ER -